BACKGROUND AND OBJECTIVE: To compare elevated intraocular pressure (IOP) management and outcomes among patients with diabetic macular edema who received fluocinolone acetonide (FAc) implants versus sham-control treatment and explore the prior ocular steroid exposure impact on IOP outcomes. PATIENTS AND METHODS: Best-corrected visual acuity (BCVA) was measured using Early Treatment Diabetic Retinopathy Study charts or electronic VA testers. Goldmann applanation tonometry was used to measure IOP. RESULTS: Elevated IOP was more common in FAcversus sham control-treated patients. Medication, and less often trabeculoplasty or surgery, was used to lower IOP without affecting VA outcomes. No patient treated with 0.2 ?g/day FAc who received prior oc...
Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetoni...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
Background: Fluocinolone acetonide (FAc) implant represents a long-term strategy for the management ...
Aims: The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study ...
Jessica D McCluskey, Paul L Kaufman, Kathy Wynne, Gregory LewisDepartment of Ophthalmology, Thomas E...
PURPOSE: To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) int...
PURPOSE: To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) int...
Objective: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-...
Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetoni...
BACKGROUND AND OBJECTIVE: To evaluate glaucomatous changes in patients with diabetic macular edema (...
Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetoni...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
International audienceINTRODUCTION: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant de...
Background: Fluocinolone acetonide (FAc) implant represents a long-term strategy for the management ...
Aims: The ILUVIEN Registry Safety Study is an ongoing, multicentre, open-label, observational study ...
Jessica D McCluskey, Paul L Kaufman, Kathy Wynne, Gregory LewisDepartment of Ophthalmology, Thomas E...
PURPOSE: To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) int...
PURPOSE: To assess the long-term safety and efficacy of the 0.19-mg fluocinolone acetonide (FAc) int...
Objective: The aim of the Iluvien Clinical Evidence study in the UK (ICE-UK) was to assess the real-...
Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetoni...
BACKGROUND AND OBJECTIVE: To evaluate glaucomatous changes in patients with diabetic macular edema (...
Objectives: To compare visual and anatomical outcomes between eyes treated with fluocinolone acetoni...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...
Purpose : evaluate the efficacy and safety of intravitreal 0.19 mg fluocinolone acetonide (FAc) micr...